Replies to post #156 on Mesoblast Ltd ADR (MESO)

[stockguard]

Mesoblast Limited looks a long way from take off
Tom Richardson | August 30, 2017 | More on: MSB


This morning regenerative medicine business Mesoblast Limited (ASX: MSB) reported a net loss before income tax benefits of US$90.2 million (A$113 million) for the financial year ending June 30, 2017. The biotech posted revenues for the year of US$2.4 million and after recently raising US$40 million now has cash on hand of US$84 million.

While the huge losses look bad the company is still valued at more than $600 million thanks to what some consider to be its large potential to generate commercial sales for its regenerative medicine stem cell therapy treatments for the likes of back pain, rheumatoid arthritis,…

https://www.fool.com.au/2017/08/30/mesoblast-limited-looks-a-long-way-from-take-off/